We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Beats on Q3 Earnings, Reiterates FY18 View
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) reported third-quarter fiscal 2018 adjusted earnings per share (EPS) of $1.17, beating the Zacks Consensus Estimate by a penny. Earnings rose 4.5% year over year.
Adjustments in the quarter primarily included the impact of restructuring charges, intangible asset amortization, divestiture-related items and acquisition-related items. After adjusting for unfavorable foreign exchange impact of a penny, adjusted EPS was $1.18.
Without these adjustments, the company’s reported a net loss of $1.03 per share, compared to 59 cents in the previous year. This included a $2.2-billion net tax expense related to the U.S. tax reform.
Total Revenues
Worldwide revenues in the reported quarter grossed $7.37 billion, up 7% on a constant exchange rate or CER basis (up 1.2% on a reported basis). The top line surpassed the Zacks Consensus Estimate of $7.20 billion. Foreign currency fluctuation favorably impacted Medtronic’s third-quarter revenues by $177 million.
In the quarter under review, U.S. sales (53.1% of total revenues) fell 4.9% year over year (up 6% at CER) to $3.91 billion. Non-U.S. developed market revenues totaled $2.36 billion (32% of total revenues), reflecting a 5% increase at CER (up 7.8% as reported). Emerging market revenues (14.9% of total revenues) amounted to $1.10 billion, up 12% at CER (up 11.8% as reported).
The company currently generates revenues from four major groups, viz. Cardiac & Vascular Group (CVG), Minimally Invasive Therapies Group (MITG), Restorative Therapies Group (RTG) and Diabetes Group.
CVG comprises Cardiac Rhythm & Heart Failure (CRHF), Coronary & Structural Heart (CSH) and Aortic & Peripheral Vascular divisions (APV). MITG now includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions after the divestiture of Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency (Enteral Feeding) businesses. RTG comprises the Spine, Brain Therapies, Specialty Therapies and Pain Therapies segments, while the Diabetes Group incorporates the Intensive Insulin Management (IIM), Non-Intensive Diabetes Therapies (NDT), and Diabetes Service & Solutions (DSS) divisions.
CVG revenues improved 7% at CER (up 10% as reported) to $2.80 billion, driven by strong, balanced growth across all three divisions.
CRHF sales totaled $1.46 billion, up 4% year over year at CER (up 6% as reported). This came on the back of growth in Arrhythmia Management led by high-teens growth in atrial fibrillation Solutions at CER, amplified penetration of the Micra transcatheter pacing system, and strong uptake of the TYRX absorbable antibacterial envelope. This apart, strong demand for the company's suite of quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drove Heart Failure division revenues.
CSH revenues were up 14% at CER (18% as reported) to $886 million on the back of low-30s constant currency growth in transcatheter aortic valves as a result of strong customer uptake of the CoreValve Evolut PRO platform and expanded FDA approval to include patients at intermediate risk. Moreover, the continued uptake of the Resolute Onyx drug-eluting stent in the United States and Japan revived the Coronary business.
APV revenues registered 5% growth at CER (up 7% as reported) to $457 million, driven by continued adoption of the Valiant Captiviathoracic stent graft systems. Peripheral was driven by double-digit growth in percutaneous transluminal angioplasty and drug-coated balloons. Moreover, solid contributions from VenaSeal closure system drove high-single digit growth in endoVenous.
In MITG, worldwide sales reached $2.04 billion, marking a 6% year-over-year increase at CER (down 16% on a reported basis) on high-single digit growth in SI, and a low-single digit growth in RGR, both at CER.
In RTG, worldwide revenues of $1.94 billion were up 5% year over year at CER (up 7% as reported) on low double-digit growth in Brain Therapies, mid-single digit growth in Specialty Therapies and high-single digit growth in Pain Therapies, at CER. However, revenues from the Spine business remained flat at CER on a year-over-year basis.
Moreover, revenues at the Diabetes group increased 13% at CER (17% as reported) to $584 million.
Margins
Gross margin in the reported quarter expanded 140 basis points (bps) to 70.3% on a 3.3% rise in gross profit to $5.18 billion. Adjusted operating margin expanded 10 bps year over year to 28.9% owing to a 5.3% rise in research and development expenses (to $558 million) along with a 4.6% uptick in selling, general and administrative expenses (to $2.49 billion). Other expenses in the reported quarter totaled $140 million as compared with $46 million in the year-ago quarter.
Guidance
Medtronic reiterated its fiscal 2018 constant-currency revenue and EPS guidance. The company maintains full-year revenue growth projection at the range of 4-5% at CER. However, the company revised its foreign currency fluctuation estimation, which is now projected to have a positive $480-$500 million impact on fiscal results compared with $275-$375 million estimated earlier. The Zacks Consensus Estimate for 2018 revenues remains at $29.50 billion.
Fiscal 2018 adjusted earnings per share growth is still expected in the range of 9-10% at CER. Currency translation is likely to have an adverse impact of 4 cents compared with the earlier expectation of a negative effect of 2 cents. The Zacks Consensus Estimate for fiscal 2018 earnings is pegged at $4.76.
For the fourth quarter of fiscal 2018, Medtronic expects currency translation to have a favorable impact of $300-$320 million on revenues. Currency translation is expected affect fourth-quarter earnings per share by 2 cents.
Our Take
Medtronic exited the fiscal third quarter on a solid note. The company demonstrated improved segmental performances at CER on growth in all business segments. However, escalating costs continue to be a concern.
Moreover, all the major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the company’s solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. Apart from product innovation, the company is focusing on geographical diversification of its businesses. Moreover, the company’s recent receipt of FDA approval for the Riptide Aspiration System under the Neurovascular unit within the RTG business buoys optimism. This adds a valuable tool to the company’s Acute Ischemic Stroke (AIS) product portfolio.
Zacks Rank & Peer Performances
Medtronic has a Zacks Rank #3 (Hold).
A few better-ranked stocks that reported solid results this earnings season are PetMed Express (PETS - Free Report) , PerkinElmer and Becton, Dickinson and Company (BDX - Free Report) . While PetMed sports a Zacks Rank #1 (Strong Buy), PerkinElmer and Becton, Dickinson carry a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank stocks here.
PetMed reported third-quarter fiscal 2018 adjusted earnings per share of 44 cents, up 88.3% from the prior-year quarter. Revenues rose 13.7% to $60.1 million.
PerkinElmer posted fourth-quarter 2017 adjusted earnings per share of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter.
Becton, Dickinson reported first-quarter fiscal 2018 adjusted earnings per share of $2.48, up 3.9% at constant currency. Revenues totaled $3.08 billion, up 3.7% at constant currency.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away. Download the new report now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medtronic (MDT) Beats on Q3 Earnings, Reiterates FY18 View
Medtronic plc (MDT - Free Report) reported third-quarter fiscal 2018 adjusted earnings per share (EPS) of $1.17, beating the Zacks Consensus Estimate by a penny. Earnings rose 4.5% year over year.
Adjustments in the quarter primarily included the impact of restructuring charges, intangible asset amortization, divestiture-related items and acquisition-related items. After adjusting for unfavorable foreign exchange impact of a penny, adjusted EPS was $1.18.
Without these adjustments, the company’s reported a net loss of $1.03 per share, compared to 59 cents in the previous year. This included a $2.2-billion net tax expense related to the U.S. tax reform.
Total Revenues
Worldwide revenues in the reported quarter grossed $7.37 billion, up 7% on a constant exchange rate or CER basis (up 1.2% on a reported basis). The top line surpassed the Zacks Consensus Estimate of $7.20 billion. Foreign currency fluctuation favorably impacted Medtronic’s third-quarter revenues by $177 million.
In the quarter under review, U.S. sales (53.1% of total revenues) fell 4.9% year over year (up 6% at CER) to $3.91 billion. Non-U.S. developed market revenues totaled $2.36 billion (32% of total revenues), reflecting a 5% increase at CER (up 7.8% as reported). Emerging market revenues (14.9% of total revenues) amounted to $1.10 billion, up 12% at CER (up 11.8% as reported).
Medtronic plc Price, Consensus and EPS Surprise
Medtronic plc Price, Consensus and EPS Surprise | Medtronic plc Quote
Segment Details
The company currently generates revenues from four major groups, viz. Cardiac & Vascular Group (CVG), Minimally Invasive Therapies Group (MITG), Restorative Therapies Group (RTG) and Diabetes Group.
CVG comprises Cardiac Rhythm & Heart Failure (CRHF), Coronary & Structural Heart (CSH) and Aortic & Peripheral Vascular divisions (APV). MITG now includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions after the divestiture of Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency (Enteral Feeding) businesses. RTG comprises the Spine, Brain Therapies, Specialty Therapies and Pain Therapies segments, while the Diabetes Group incorporates the Intensive Insulin Management (IIM), Non-Intensive Diabetes Therapies (NDT), and Diabetes Service & Solutions (DSS) divisions.
CVG revenues improved 7% at CER (up 10% as reported) to $2.80 billion, driven by strong, balanced growth across all three divisions.
CRHF sales totaled $1.46 billion, up 4% year over year at CER (up 6% as reported). This came on the back of growth in Arrhythmia Management led by high-teens growth in atrial fibrillation Solutions at CER, amplified penetration of the Micra transcatheter pacing system, and strong uptake of the TYRX absorbable antibacterial envelope. This apart, strong demand for the company's suite of quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drove Heart Failure division revenues.
CSH revenues were up 14% at CER (18% as reported) to $886 million on the back of low-30s constant currency growth in transcatheter aortic valves as a result of strong customer uptake of the CoreValve Evolut PRO platform and expanded FDA approval to include patients at intermediate risk. Moreover, the continued uptake of the Resolute Onyx drug-eluting stent in the United States and Japan revived the Coronary business.
APV revenues registered 5% growth at CER (up 7% as reported) to $457 million, driven by continued adoption of the Valiant Captiviathoracic stent graft systems. Peripheral was driven by double-digit growth in percutaneous transluminal angioplasty and drug-coated balloons. Moreover, solid contributions from VenaSeal closure system drove high-single digit growth in endoVenous.
In MITG, worldwide sales reached $2.04 billion, marking a 6% year-over-year increase at CER (down 16% on a reported basis) on high-single digit growth in SI, and a low-single digit growth in RGR, both at CER.
In RTG, worldwide revenues of $1.94 billion were up 5% year over year at CER (up 7% as reported) on low double-digit growth in Brain Therapies, mid-single digit growth in Specialty Therapies and high-single digit growth in Pain Therapies, at CER. However, revenues from the Spine business remained flat at CER on a year-over-year basis.
Moreover, revenues at the Diabetes group increased 13% at CER (17% as reported) to $584 million.
Margins
Gross margin in the reported quarter expanded 140 basis points (bps) to 70.3% on a 3.3% rise in gross profit to $5.18 billion. Adjusted operating margin expanded 10 bps year over year to 28.9% owing to a 5.3% rise in research and development expenses (to $558 million) along with a 4.6% uptick in selling, general and administrative expenses (to $2.49 billion). Other expenses in the reported quarter totaled $140 million as compared with $46 million in the year-ago quarter.
Guidance
Medtronic reiterated its fiscal 2018 constant-currency revenue and EPS guidance. The company maintains full-year revenue growth projection at the range of 4-5% at CER. However, the company revised its foreign currency fluctuation estimation, which is now projected to have a positive $480-$500 million impact on fiscal results compared with $275-$375 million estimated earlier. The Zacks Consensus Estimate for 2018 revenues remains at $29.50 billion.
Fiscal 2018 adjusted earnings per share growth is still expected in the range of 9-10% at CER. Currency translation is likely to have an adverse impact of 4 cents compared with the earlier expectation of a negative effect of 2 cents. The Zacks Consensus Estimate for fiscal 2018 earnings is pegged at $4.76.
For the fourth quarter of fiscal 2018, Medtronic expects currency translation to have a favorable impact of $300-$320 million on revenues. Currency translation is expected affect fourth-quarter earnings per share by 2 cents.
Our Take
Medtronic exited the fiscal third quarter on a solid note. The company demonstrated improved segmental performances at CER on growth in all business segments. However, escalating costs continue to be a concern.
Moreover, all the major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the company’s solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. Apart from product innovation, the company is focusing on geographical diversification of its businesses. Moreover, the company’s recent receipt of FDA approval for the Riptide Aspiration System under the Neurovascular unit within the RTG business buoys optimism. This adds a valuable tool to the company’s Acute Ischemic Stroke (AIS) product portfolio.
Zacks Rank & Peer Performances
Medtronic has a Zacks Rank #3 (Hold).
A few better-ranked stocks that reported solid results this earnings season are PetMed Express (PETS - Free Report) , PerkinElmer and Becton, Dickinson and Company (BDX - Free Report) . While PetMed sports a Zacks Rank #1 (Strong Buy), PerkinElmer and Becton, Dickinson carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported third-quarter fiscal 2018 adjusted earnings per share of 44 cents, up 88.3% from the prior-year quarter. Revenues rose 13.7% to $60.1 million.
PerkinElmer posted fourth-quarter 2017 adjusted earnings per share of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter.
Becton, Dickinson reported first-quarter fiscal 2018 adjusted earnings per share of $2.48, up 3.9% at constant currency. Revenues totaled $3.08 billion, up 3.7% at constant currency.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>